TP
ACAD icon

Thunderbird Partners’s Acadia Pharmaceuticals ACAD Stock Holding History

Thunderbird Partners’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-692,825
Closed -$16.8M – 11
2022
Q1 		$16.8M Buy
+692,825
New +$16.8M 2.38% 10

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Thunderbird Partners's ACAD Position: Q2 2022 in Review

Thunderbird Partners sold out of Acadia Pharmaceuticals (ACAD) in Q2 2022, closing a stake of 692,825 shares — an estimated $16.8M sold.

Thunderbird Partners first reported a position in ACAD in Q1 2022 and held it in 1 quarter. The position peaked at $16.8M in Q1 2022. 246 funds tracked by Wall St. Rank hold ACAD as of Q2 2022.

  • Thunderbird Partners reported no remaining Acadia Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Thunderbird Partners sold 692,825 Acadia Pharmaceuticals shares in Q2 2022, an estimated $16.8M.
  • Thunderbird Partners first reported a position in Acadia Pharmaceuticals in Q1 2022 and held it in 1 quarter.
  • Thunderbird Partners's Acadia Pharmaceuticals position peaked at $16.8M in Q1 2022.
  • 246 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2022.

Based on Thunderbird Partners's 13F filing for Q2 2022, filed 15 Aug 2022.